1.00
-0.0099(-0.98%)
Currency In USD
| Previous Close | 1.01 |
| Open | 0.98 |
| Day High | 1 |
| Day Low | 0.95 |
| 52-Week High | 4.22 |
| 52-Week Low | 0.85 |
| Volume | 15,748 |
| Average Volume | 26,691 |
| Market Cap | 16,307 |
| PE | -0.39 |
| EPS | -2.58 |
| Moving Average 50 Days | 1.12 |
| Moving Average 200 Days | 1.27 |
| Change | -0.01 |
If you invested $1000 in Akari Therapeutics, Plc (AKTX) 10 years ago, it would be worth $4.9 as of August 18, 2025 at a share price of $1. Whereas If you bought $1000 worth of Akari Therapeutics, Plc (AKTX) shares 5 years ago, it would be worth $27.17 as of August 18, 2025 at a share price of $1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
GlobeNewswire Inc.
Aug 14, 2025 1:15 PM GMT
Live video webcast on Tuesday, August 19th at 2:00 PM ETBOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology paylo
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
GlobeNewswire Inc.
Jul 29, 2025 1:15 PM GMT
Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari’s commitment to continued research to better understand the multiple effects of its novel spliceosome modulator, PH1Watch the “What This Means” video here BOSTON and LONDON,
Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
GlobeNewswire Inc.
Jul 23, 2025 12:55 PM GMT
PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of ADCs using PH1 payload across both Trop2 and an undisclosed target Emerging new preclinical d